B · Normal
[Shanghai Pharmaceutical: Clevidipine Emulsive Injection Approved for Production] On October 9, Shanghai Pharmaceuticals (601607.SH) announced that the company's subsidiary Shanghai Pharmaceuticals First Biochemical received the "Drug Registration Certificate" for clevidipine emulsive injection issued by the State Food and Drug Administration, and the drug was approved for production. This drug is mainly used to treat high blood pressure that is not suitable for oral administration or where oral medication is not expected to be effective. As of the announcement date, the company has invested approximately 52.2 million yuan in research and development expenses for this drug.
Comments